Archive | Clinical Trials

Tumor Growth Blocked by Potato Virus-Chemo Combo

Newswise — Researchers funded by the National Institute of Biomedical Imaging and Bioengineering combined the immune response created by injection of potato virus nanoparticles with the chemotherapy drug doxorubicin to halt melanoma progression in a mouse model.

Read the full story

Posted in Melanoma In The News, Clinical Trials

CheckMate 238: Nivolumab Shows Benefit as Adjuvant Melanoma Treatment

IN THE TREATMENT of malignant melanoma, immune checkpoint inhibitors are no longer just for metastatic disease, and the best type may be agents targeting the programmed cell death protein 1 (PD-1), according to results of CheckMate 238, presented at the European Society for Medical Oncology (ESMO) 2017 Congress by Jeffrey Weber, MD, Deputy Director of the […]

Read the full story

Posted in Melanoma In The News, Clinical Trials

Nivolumab/Ipilimumab in Patients With Advanced Melanoma Who Did or Did Not Discontinue Induction Treatment due to Adverse Events

IN A RETROSPECTIVE pooled analysis of the CheckMate 069 and 067 studies reported in the Journal of Clinical Oncology, Dirk Schadendorf, MD, of the University Hospital Essen and the German Cancer Consortium, and colleagues found little difference in the efficacy of combined nivolumab (Opdivo) and ipilimumab (Yervoy) among patients with advanced melanoma who discontinued or […]

Read the full story

Posted in Melanoma In The News, Clinical Trials

BRAF/MEK Combinations Continue to Revolutionize Melanoma Landscape

The BRAF/MEK inhibitor combination of dabrafenib (Tafinlar) and trametinib (Mekinist) was found to reduce the risk of relapse or death by 53% compared with placebo for patients with BRAF-mutant stage III melanoma, according to findings from the phase III COMBI-AD study.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories